Amisulpride Augmentation in Acute Catatonia

Manu Arora, Rakesh Banal, Samir K. Praharaj, Vivek Mahajan

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Benzodiazepines are the first-line treatment of catatonia, but a substantial number of patients do not respond to them. Amisulpride is one of the atypical antipsychotic that has been effective for negative symptoms of schizophrenia. We examined the effect of augmentation of oral low doses of amisulpride with lorazepam on resolution of catatonic symptoms. Fifteen patients with catatonia were treated with a combination of oral lorazepam (2-4 mg) with amisulpride (100 mg). Catatonic symptoms were rated using the Bush Francis Catatonia Rating Scale at the baseline and daily thereafter. There was complete resolution of catatonic symptoms on the third day in all patients. There was significant reduction of the total Bush Francis Catatonia Rating Scale score over time (F = 181.38, P < 0.001) with a strong effect size (partial η 2 = 0.96). Augmentation of lorazepam with low-dose amisulpride can be a reliable strategy for management of catatonia.

Original languageEnglish
Pages (from-to)e381-e385
JournalAmerican Journal of Therapeutics
Issue number4
Publication statusPublished - 01-01-2017

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Amisulpride Augmentation in Acute Catatonia'. Together they form a unique fingerprint.

Cite this